Abstract
Bacharier LB, Raissy HH, Wilson L, McWilliams B, Strunk RC, Kelly HW. Pediatrics . 2004;113:1693–1699 To determine the safety of 36 months of inhaled budesonide administration on hypothalamic-pituitary-adrenal (HPA) axis function in children with mild to moderate asthma. Sixty-three children enrolled in the previously published Childhood Asthma Management Program (CAMP) study with mild to moderate asthma (mean age: 9.5 ± 1.9 years). CAMP participants were between 5 and 12 years of age. Children received placebo, nedocromil (16 mg/day by metered-dose inhaler), or budesonide (400 μg/day by Turbuhaler). HPA axis function was assessed at baseline and after 12 and 36 …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
